BiotechTube

PI3K inhibitor BKM120 + docetaxel

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Unspecified Adult Solid Tumor, Protocol Specific

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Trial Timeline

May 1, 2012 → Jun 1, 2016

NCT ID
NCT01540253

About PI3K inhibitor BKM120 + docetaxel

PI3K inhibitor BKM120 + docetaxel is a phase 1 stage product being developed by Novartis for Unspecified Adult Solid Tumor, Protocol Specific. The current trial status is completed. This product is registered under clinical trial identifier NCT01540253. Target conditions include Unspecified Adult Solid Tumor, Protocol Specific.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01540253Phase 1Completed

Competing Products

20 competing products in Unspecified Adult Solid Tumor, Protocol Specific

See all competitors
ProductCompanyStageHype Score
DJ-927 + capecitabineDaiichi SankyoPhase 1
33
E7389 + E7389 + E7389EisaiPhase 1
33
bevacizumab + enzastaurin hydrochlorideEli LillyPhase 1
33
SHR-1916Jiangsu Hengrui MedicinePhase 1
33
PembrolizumabMerckPhase 2
52
bevacizumab + cyclophosphamide + imatinibNovartisPhase 1
33
capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)NovartisPhase 1
33
warfarinNovartisPhase 1
33
RLY-1971RochePhase 1
33
Domvanalimab + ZimberelimabGilead SciencesPhase 1
32
BEZ235 + MEK162PfizerPhase 1
32
Utomilumab + ISA101bPfizerPhase 2
51
IrinotecanPfizerPhase 1
32
Ixabepilone + SunitinibPfizerPhase 1
32
ixabepilone + lapatinib ditosylateBristol Myers SquibbPhase 1
32
carboplatin + irinotecan hydrochlorideBristol Myers SquibbPhase 1
32
intoplicineSanofiPhase 1
32
apomineSanofiPhase 1
32
apomineSanofiPhase 1
32
SorafenibBayerPhase 2
49

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85